- Home
- Companies
- T2 Biosystems, Inc.
- Products
- T2Biothreat Panel
T2Biothreat Panel
Detection of biothreat pathogens in 3-5 hours— direct from whole blood: The T2Biothreat® Panel, which runs on the T2Dx® Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including B. anthracis, F. tularensis, B. mallei , B. pseudomallei, Y. pestis, and R. prowazekii. Clinical Trial: The T2Biothreat clinical trial for evaluating the Panel was initiated in December 2021, and will support a submission to the U.S. Food and Drug Administration (FDA).
T2MR® Technology: The T2Biothreat Panel utilizes the same T2MR® Technology and T2Dx Instrument as the T2Bacteria® and T2Candida® Panels – the first and only FDA-cleared and CE-marked panels for detection of sepsis-causing bloodstream infections direct from a patient’s blood sample, without requiring blood culture results.